Vnitr Lek 2016, 62(Suppl 4):48-51

OxLDL/β2-glycoprotein I complex as a pro-atherogenic autoantigen. Is atherosclerosis an autoimmune disease?

Pavel Kraml
Centrum pro výzkum diabetu, metabolizmu a výživy II. interní kliniky 3. LF UK a FN Královské Vinohrady, Praha

Oxidation of atherogenic low-density lipoproteins (LDL) plays a key role in the pathogenesis of atherosclerosis. Oxidation stress and inflammation are closely interrelated and they can potentiate one another. In the subendothelial space of the arterial intima, monocytes/macrophages become activated and phagocyte oxidized LDL (oxLDL) via scavenger receptors. It has been demonstrated that oxLDL forms complex with plasma β2-glycoprotein I (β2GPI) and becomes autoantigenic triggering synthesis of specific antiphosholipid antibodies. It has been documented that oxLDL/β2GPI in immune complex with IgG autoantibody is internalized by macrophages through the Fcγ receptor. Increased levels of oxLDL/β2GPI were first observed in patients with systemic lupus erythematodes (SLE) and antiphospholipid syndrome (APS), further in individuals with coronary heart disease (CHD) and type 2 diabetes mellitus (DM2T). In a prospective study, initial plasma concentrations of oxLDL/β2GPI correlated with the number and severity of cardiovascular events in patients with chronic CHD over a 2-year period.

Keywords: atherosclerosis; β2-glycoprotein I; inflammation; oxidative stress; oxLDL

Received: August 30, 2016; Accepted: October 11, 2016; Published: August 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kraml P. OxLDL/β2-glycoprotein I complex as a pro-atherogenic autoantigen. Is atherosclerosis an autoimmune disease? Vnitr Lek. 2016;62(Supplementum 4):48-51.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anderson MT, Staal FJ, Gitler C et al. Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway. Prc Natl Acad Sci USA 1994; 91(24): 11527-11531. Go to original source... Go to PubMed...
    2. Flohé L, Brigelius-Flohé R, Saliou C et al. Redox regulation of NF-kappa B activation. Free Radic Biol Med 1997; 22(6): 1115-1126. Go to original source... Go to PubMed...
    3. Murphy JE, Tedbury PR, Homer-Vanniasinkam S et al. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 2005; 182(1): 1-15. Go to original source... Go to PubMed...
    4. Brown MS, Goldstein JL. A Receptor-Mediated Pathway for Cholesterol Homeostasis. Science 1986; 232(4746): 34-47. Go to original source... Go to PubMed...
    5. de Villiers WJ, Smart EJ. Macrophage scavenger receptors and foam cells formation. J Leukoc Biol 1999; 66(5): 740-746. Go to original source... Go to PubMed...
    6. Hasunuma Y, Matsuura E, Makita Z et al. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107(3): 569-573. Go to original source... Go to PubMed...
    7. Lozier J, Takahashi N, Putman FW. Complete amino acid seqnence of human plasma β2glycoprotein I. Proc Natl Acad Sci USA 1984; 81(12): 3640-3644. Go to original source... Go to PubMed...
    8. Kristensen T, Schousbe I, Boel E et al. Molecular cloning gand mammalian expression of human beta 2-glycoprotein I cDNA. FEBS Lett 1991; 289(2): 183-186. Go to original source... Go to PubMed...
    9. Agar C, van Os GM, Mörgelein M et al. Beta2-Glycoprotein I can exist in two conformations: implication for our understanding of the antiphospholipid syndrome. Blood 2010; 116(8): 1336-1343. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2009-12-260976>. Go to original source... Go to PubMed...
    10. George J, Harats D, Gilburd B et al. Immunolocalization of beta2-glycoprotein I (apoliporotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999; 99(17): 2227-2230. Go to original source... Go to PubMed...
    11. Kobayashi K, Kishi M, Atsui T et al. Circulating oxidized low density lipoprotein forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003; 44(4): 716-726. Go to original source... Go to PubMed...
    12. Ylä-Herttuala S, Palinski W, Rosenfeld ME et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84(4): 1086-1095. Go to original source... Go to PubMed...
    13. Kajiwara T, Yasuda T, Matsuura E. Intracellular trafficking of β2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome. J Autoimmun 2007; 29(2-3): 164-173. Go to original source... Go to PubMed...
    14. Matsuura E, Hughes GR, Khamashta MA. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008; 7(7): 558-566. Dostupné z DOI: <http://dx.doi.org/10.1016/j.autrev.2008.04.018>. Go to original source... Go to PubMed...
    15. Monroe DM, Key NS. The tissue factor-factor VIIa complex: procoagulant activity, tegulation, and multitasking. J Thromb Haemost 2007; 5(6): 1097-1105. Go to original source... Go to PubMed...
    16. Malia RG, Kitchen S, Greaves M et al. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 1990; 76(1): 101-107. Go to original source... Go to PubMed...
    17. Ieko M, Sawada KI, Koike T et al. The putative mechanism of thrombosis in antiphospholipid syndrome: impairment of the protein C and the fibrinoltic systems by monoclonal anticardiolipidn antibodies. Semin Thromb Hemost 1999; 25(5): 503-507. Go to original source... Go to PubMed...
    18. de Laat B, Eckmann CM, van Schagen M et al. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood Coagul Fibrubikysus 2008; 19(8): 757-764. Dostupné z DOI: <http://dx.doi.org/10.1097/MBC.0b013e32830f1b85>. Go to original source... Go to PubMed...
    19. Kobayashi K, Matsuura E, Liu Q et al. A specific ligand for β2-glycoprotein I mediates antibody-dependent uptake of oxidized low-density lipoproteins by macrophages. J Lipid Res 2001; 42(5): 697-709. Go to original source...
    20. Liu Q, Kobayashi K, Inagaki J et al. w-Carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res 2002: 43(9): 1486-1495. Go to original source... Go to PubMed...
    21. Greco TP, Conti-Kelly AM, Anthony JR et al. Oxidized-LDL/ β2-glycoprotein I Complexes Are Associated With Disease Severity and Increased Risk for Adverse Outcomes in Patients With Acute Coronary Syndromes. Am J Clin Pathol 2010; 133(5): 737-743. Dostupné z DOI: <http://dx.doi.org/10.1309/AJCP88WVRDRDFBAS>. Go to original source... Go to PubMed...
    22. Ames PR j, Ortiz-Cadanas A, Garcia-De La Torre I et al. Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein I complex concentration in type 2 diabetes. Br J Diabetes Vasc Dis 2010; 10(6): 292-299. Go to original source...
    23. Lopez LR, Hurley BL, Simpson DF et al. Oxidized low-density lipoprotein/ β2-glycoprotein I complex I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann NY Acad Sci 2005; 1051: 97-103. Go to original source... Go to PubMed...
    24. Kraml PJ, Syrovátka P, Potočková J et al. The oxidized low-density lipoprotein/ β2-glycoprotein I complex is associated with abdominal obesity in healthy middle-aged men. Ann Nutr Med 2013; 62(1): 7-13. Dostupné z DOI: <http://dx.doi.org/10.1159/000343049>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.